Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Clinical Trial ID NCT02136134

PubWeight™ 9.49^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02136134

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.	N Engl J Med	2016	2.32
2	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.	Blood	2022	1.39
3	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.	Blood	2016	0.98
4	Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives.	Leukemia	2015	0.92
5	Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.	Immunol Rev	2016	0.91
6	Promising therapies in multiple myeloma.	Blood	2015	0.89
7	Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity.	Bone Marrow Transplant	2016	0.82
8	Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development.	Ther Adv Hematol	2015	0.79
9	Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.	J Hematol Oncol	2016	0.79
10	The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.	Adv Ther	2016	0.75
11	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.	J Hematol Oncol	2020	0.75
12	Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review.	Case Rep Oncol Med	2016	0.75